Healthy volunteers help compare new biosimilar to taltz

NCT ID NCT07200986

First seen Jun 27, 2026 ยท Last updated Jun 27, 2026

Summary

This study tests whether a new biosimilar medicine (CT-P52) works similarly to the approved drug Taltz in the body. It involves 218 healthy adults aged 19 to 55 who receive a single dose of either the biosimilar or Taltz. The main goal is to compare how the drug is absorbed and its safety, not to treat any disease.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary โ€” we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEALTHY PARTICIPANTS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • CHA Bundang Medical Center

    Seongnam-si, Gyeonggi-do, South Korea

  • Chungbuk National University Hospital

    Cheongju-si, North Chungcheong, South Korea

  • Inje University Busan Paik Hospital

    Busan, Busanjin-gu, South Korea

  • Seoul National University Bundang Hospital

    Seongnam-si, Gyeonggi-do, South Korea

  • Seoul National University Hospital

    Seoul, South Korea